Table 2.
Groups | Parameters |
|||||
---|---|---|---|---|---|---|
Bilirubin (mg/dl) n (7) |
TP (g/dl) n (7) |
Albumin (g/dl) n (7) |
AST (U/L) n (7) |
ALT (U/L) n (7) |
ALP mcg/L n (7) |
|
Control | 0.43 ± 0.020# | 7.64 ± 0.15# | 4.92 ± 0.298# | 19.85 ± 2.91# | 19.28 ± 3.03# | 223.28 ± 26.47# |
OS | 2.20 ± 0.22* | 3.35 ± 0.25* | 1.54 ± 0.222* | 100.28 ± 5.76* | 99.85 ± 5.87* | 698.00 ± 9.00* |
OS + CMF | 1.64 ± 0.198*# | 4.88 ± 0.27*# | 2.01 ± 0.307*# | 81.42 ± 3.20*# | 80.71 ± 4.71*# | 593.00 ± 30.5*# |
OS + CMF_LDS | 0.89 ± 0.028*# | 5.71 ± 0.22*# | 3.04 ± 0.171*# | 66.42 ± 4.68*# | 64.00 ± 1.82*# | 432.28 ± 16.5*# |
OS + CMF + HDS | 0.67 ± 0.026*# | 6.45 ± 0.17*# | 4.10 ± 0.230*# | 56.71 ± 2.28*# | 49.57 ± 1.71*# | 350.71 ± 40.5*# |
OS, osteosarcoma; CMF, cocktail of chemotherapy drugs; LDS, low dose shilajit; HDS, high dose shilajit; TP, total protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALT, alkaline phosphatase. Data are expressed as mean ± SD, *p < 0.05 as compared to control ans #p < 0.05 compared to OS group.